VolitionRx Announces Sponsorship of a Pioneering Webinar
VolitionRx Limited (NYSE AMERICAN: VNRX), a global leader in epigenetics, is taking an exciting step forward by sponsoring an engaging GenomeWeb webinar. This event, titled "Beyond the Genome: Measuring Epigenetic Modifications Across Matrices for Biomarker and Drug Discovery," aims to shed light on the critical roles epigenetics plays in health and disease.
Webinar Insights and Expert Speakers
The webinar, set for a Wednesday morning, is designed to provide participants with in-depth knowledge and cutting-edge research findings. Dr. Jasmine Kway, the Chief Executive Officer of Singapore Volition, shared her excitement about the upcoming event: "This webinar will showcase our Nu.Q® Discover service and highlight how it equips drug developers and scientists with advanced assays for rapid epigenetic profiling in various research contexts."
Esteemed speakers Dr. Eric Ariazi and Dr. Marielle Herzog will lead discussions filled with crucial insights. Dr. Ariazi, a translational cancer biologist, will highlight significant epigenetic pathways, focusing on the PRC2 complex and its implications in cancer. His presentations will cover key preclinical and clinical studies involving pharmacological inhibitors, reinforcing the potential of combining therapies for improved cancer treatments.
Case Studies and Practical Applications
Dr. Herzog, the R&D director at Belgian Volition, will further elaborate on practical applications of the Nu.Q assays. These assays have been developed in accordance with CLSI guidelines, demonstrating the potential to contribute effectively to disease research and clinical developmental practices, particularly in the realm of epigenetics.
About Nu.Q® Discover Service
Volition’s Nu.Q® Discover program is a state-of-the-art resource enabling scientists and drug developers to perform rapid epigenetic profiling. The technology is grounded in proprietary nucleosome quantification, making it a vital tool for researchers exploring pharmaco-epigenetics—investigating how a patient's genetics influence their response to treatments.
Volition: A Company Committed to Advancing Epigenetics
Volition plays a crucial role in advancing the field of epigenetics. By dedicating resources to the development of simple, effective blood tests for diagnosing and monitoring multiple diseases—including various cancers—Volition is dedicated to enhancing patient outcomes through early detection and ongoing monitoring.
With its research hubs in Belgium and the U.S., Volition is strategically positioned to innovate and lead in this essential field. The company's commitment revolves around saving lives by providing vital tools for medical professionals.
Media Inquiries and Connections
For further information, Louise Batchelor from Volition can be reached for media inquiries through the provided contact details. For investor relations queries, Jeremy Feffer from LifeSci Advisors is available to assist.
Frequently Asked Questions
What is the purpose of the Webinar sponsored by Volition?
The webinar aims to highlight the importance of epigenetic modifications in biomarker and drug discovery, showcasing Volition's innovative technologies.
Who are the speakers at the webinar?
Dr. Eric Ariazi and Dr. Marielle Herzog will be presenting at the webinar, providing insights into epigenetic pathways and practical applications of Volition's assays.
What technology does Nu.Q® Discover implement?
Nu.Q® Discover utilizes proprietary nucleosome quantification technology to enable rapid epigenetic profiling across various disease models.
How does Volition contribute to healthcare?
Volition develops innovative blood tests that enhance early detection and monitoring of diseases, ultimately improving patient outcomes.
Where are Volition's research activities based?
Volition's research facilities are predominantly in Belgium, with additional offices in the U.S. and London, supporting global innovation in epigenetics.
